Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs

Eschweiler, Simon; Ramírez-Suástegui, Ciro; Li, Yingcong; V. King, Emma; Chudley, Lindsey; Thomas, Jaya; Wood, Oliver; von Witzleben, Adrian; Lifson Jeffrey, D.; J. McCann, Katy; Simon, Hayley; Mondal, Monalisa; Wang, Alice; Dicker, Martina; Lopez-Guadamillas, Elena; Chou, Ting-Fang; Dobbs, Nicola; Essame, Louisa; D Acton, Gary; Kelly, Fiona; Halbert, Gavin; J. Sacco, Joseph; Schache, Andrew; Shaw, Richard; McCaul, James; Paterson, Claire; H. Davies, Joseph; A. Brennan, Peter; Prasad Singh, Rabindra; M. Loadman, Paul; Wilson, William; Hackshaw, Allan; Seumois, Grégory; Okkenhaug, Klaus; J. Thomas, Gareth; M. Jones, Terry; Ay, Ferhat; Friberg, Greg; Kronenberg, Mitchell; Vanhaesebroeck, Bart; Vijayanand, Pandurangan; H. Ottensmeier, Christian

doi:10.1038/s41586-022-04685-2

Public

Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs

Published in Nature • May 4, 2022

Authors:

Simon Eschweiler

Ciro Ramírez-Suástegui

Yingcong Li

Abstract

Abstract Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies 1–3 . Although studies in mouse models of solid tumours have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumour imm...

Subject

PI3K/AKT/mTOR pathway

Medicine

Cancer research

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!